Evidence map›Paper›PMID 33756475›Full record

ReviewChemotherapy2021

Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection.

Ornella Spagnolello, Claudia Pinacchio, Letizia Santinelli, Paolo Vassalini, Giuseppe Pietro Innocenti, Gabriella De Girolamo, Silvia Fabris, Marta Giovanetti, Silvia Angeletti, Alessandro Russo and 4 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Risk factors for carbapenem-resistantJAC-antimicrobial resistance · 2023
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Clinical features and mechanistic insights into drug repurposing for combating COVID-19.The international journal of biochemistry & cell biology · 2022
    Review
  13. Review
  14. Review
  15. From Pre- and Probiotics to Post-Biotics: A Narrative Review.International journal of environmental research and public health · 2021
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Ornella SpagnolelloDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Claudia PinacchioDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Letizia SantinelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Paolo VassaliniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Giuseppe Pietro InnocentiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Gabriella De GirolamoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Silvia FabrisMedical Statistic and Molecular Epidemiology Unit, University of Biomedical Campus, Rome, Italy.
Marta GiovanettiMedical Statistic and Molecular Epidemiology Unit, University of Biomedical Campus, Rome, Italy.
Silvia AngelettiUnit of Clinical Laboratory Science, University of Biomedical Campus, Rome, Italy.
Alessandro RussoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Claudio M MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Massimo CiccozziMedical Statistic and Molecular Epidemiology Unit, University of Biomedical Campus, Rome, Italy.
Giancarlo CeccarelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, giancarlo.ceccarelli@uniroma1.it.
Gabriella d'EttorreDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITUniversità Campus Bio-Medico · ITFundação Oswaldo Cruz · BRWorld Health Organization - Italy · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory and gastrointestinal symptoms are the predominant clinical manifestations of the coronavirus disease 2019 (COVID-19). Infecting intestinal epithelial cells, the severe acute respiratory syndrome coronavirus-2 may impact on host's microbiota and gut inflammation. It is well established that an imbalanced intestinal microbiome can affect pulmonary function, modulating the host immune response ("gut-lung axis"). While effective vaccines and targeted drugs are being tested, alternative pathophysiology-based options to prevent and treat COVID-19 infection must be considered on top of the limited evidence-based therapy currently available. Addressing intestinal dysbiosis with a probiotic supplement may, therefore, be a sensible option to be evaluated, in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration in preventing and treating COVID-19 pneumonia.

Indexed as

COVID-19DysbiosisDietary SupplementsGastrointestinal MicrobiomeHumansProbioticsSARS-CoV-2COVID-19DysbiosisGut-lung axisProbioticsSystemic cytokine storm

Identifiers

PMID33756475
PMCPMC8089442
OpenAlexW3136906582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.